Boston Scientific (BSX) Stock Forecast & Price Target

Compare

3,284 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BSX Analyst Ratings

Strong Buy

22 Buy

1 Hold

0 Sell

Based on 23 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$120.29

▲(18.66%Upside)

Based on 23 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $120.29 with a high forecast of $135.00 and a low forecast of $110.00. The average price target represents a 18.66% change from the last price of $101.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","105":"$105","136":"$136","89.5":"$89.5","120.5":"$120.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$120.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,89.5,105,120.5,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.17,106.54153846153847,108.91307692307693,111.28461538461539,113.65615384615384,116.0276923076923,118.39923076923077,120.77076923076923,123.1423076923077,125.51384615384615,127.88538461538462,130.25692307692307,132.62846153846152,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.17,105.41,106.65,107.89,109.13000000000001,110.37,111.61,112.85000000000001,114.09,115.33000000000001,116.57000000000001,117.81,119.05000000000001,{"y":120.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.17,104.61846153846155,105.06692307692308,105.51538461538462,105.96384615384615,106.41230769230769,106.86076923076924,107.30923076923077,107.75769230769231,108.20615384615385,108.65461538461538,109.10307692307693,109.55153846153846,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.57,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.41,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$120.29

Lowest Price Target$110.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$113

Buy

11.47%

Upside

Reiterated

06/17/25

Boston Scientific's overall stock score reflects its strong financial performance and positive earnings outlook, which are partially offset by high valuation and mixed technical indicators. The company's strategic initiatives in cardiology and electrophysiology are driving growth, though external challenges like tariffs and regulatory pressures present risks.

Mike KratkyLeerink Partners

Leerink Partners

$118

Buy

16.41%

Upside

Initiated

06/16/25

Boston Scientific initiated with an Outperform at LeerinkBoston Scientific initiated with an Outperform at Leerink

Larry BiegelsenWells Fargo

Wells Fargo

$118

Buy

16.41%

Upside

Reiterated

06/15/25

Boston Scientific's Strong Market Position and Innovative Pipeline Drive Buy Rating

Travis SteedBank of America Securities

Bank of America Securities

―

Buy

―

Reiterated

06/05/25

Boston Scientific (BSX) Gets a Buy from Bank of America Securities

Lee HambrightBernstein

Bernstein

$124

Buy

22.32%

Upside

Reiterated

06/04/25

Bernstein Remains a Buy on Boston Scientific (BSX)

Matthew O'BrienPiper Sandler

Piper Sandler

$115

Buy

13.45%

Upside

Reiterated

05/30/25

Boston Scientific (BSX) Gets a Buy from Piper Sandler

Joanne WuenschCiti

Citi

$125

Buy

23.31%

Upside

Reiterated

05/28/25

Boston Scientific's Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return

Robbie MarcusJ.P. Morgan

J.P. Morgan

$135

Buy

33.18%

Upside

Reiterated

05/28/25

J.P. Morgan Reaffirms Their Buy Rating on Boston Scientific (BSX)

Matt MiksicBarclays

Barclays

$125

Buy

23.31%

Upside

Reiterated

05/28/25

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)

Josh JenningsTD Cowen

TD Cowen

$115

Buy

13.45%

Upside

Reiterated

05/28/25

TD Cowen Sticks to Their Buy Rating for Boston Scientific (BSX)

Vijay KumarEvercore ISI

Evercore ISI

$112

Buy

10.49%

Upside

Reiterated

05/28/25

Evercore ISI Sticks to Its Buy Rating for Boston Scientific (BSX)

Michael MatsonNeedham

Needham

$115

Buy

13.45%

Upside

Reiterated

05/28/25

Boston Scientific's Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations

Jayson BedfordRaymond James

Raymond James

$121

Buy

19.36%

Upside

Reiterated

05/27/25

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Haemonetics (HAE)

Rick WiseStifel Nicolaus

Stifel Nicolaus

$115→$120

Buy

18.38%

Upside

Reiterated

05/27/25

Stifel Nicolaus Keeps Their Buy Rating on Boston Scientific (BSX)

Patrick WoodMorgan Stanley

Morgan Stanley

$120→$125

Buy

23.31%

Upside

Reiterated

05/16/25

Morgan Stanley Sticks to Its Buy Rating for Boston Scientific (BSX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$113

Buy

11.47%

Upside

Reiterated

06/17/25

Mike KratkyLeerink Partners

Leerink Partners

$118

Buy

16.41%

Upside

Initiated

06/16/25

Boston Scientific initiated with an Outperform at LeerinkBoston Scientific initiated with an Outperform at Leerink

Larry BiegelsenWells Fargo

Wells Fargo

$118

Buy

16.41%

Upside

Reiterated

06/15/25

Boston Scientific's Strong Market Position and Innovative Pipeline Drive Buy Rating

Travis SteedBank of America Securities

Bank of America Securities

―

Buy

―

Reiterated

06/05/25

Boston Scientific (BSX) Gets a Buy from Bank of America Securities

Lee HambrightBernstein

Bernstein

$124

Buy

22.32%

Upside

Reiterated

06/04/25

Bernstein Remains a Buy on Boston Scientific (BSX)

Matthew O'BrienPiper Sandler

Piper Sandler

$115

Buy

13.45%

Upside

Reiterated

05/30/25

Boston Scientific (BSX) Gets a Buy from Piper Sandler

Joanne WuenschCiti

Citi

$125

Buy

23.31%

Upside

Reiterated

05/28/25

Boston Scientific's Strategic Shift and Resilient Outlook: A Buy Rating with 17.7% Expected Return

Robbie MarcusJ.P. Morgan

J.P. Morgan

$135

Buy

33.18%

Upside

Reiterated

05/28/25

J.P. Morgan Reaffirms Their Buy Rating on Boston Scientific (BSX)

Matt MiksicBarclays

Barclays

$125

Buy

23.31%

Upside

Reiterated

05/28/25

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Axsome Therapeutics (AXSM)

Josh JenningsTD Cowen

TD Cowen

$115

Buy

13.45%

Upside

Reiterated

05/28/25

TD Cowen Sticks to Their Buy Rating for Boston Scientific (BSX)

Vijay KumarEvercore ISI

Evercore ISI

$112

Buy

10.49%

Upside

Reiterated

05/28/25

Evercore ISI Sticks to Its Buy Rating for Boston Scientific (BSX)

Michael MatsonNeedham

Needham

$115

Buy

13.45%

Upside

Reiterated

05/28/25

Boston Scientific's Strategic Shift and Growth Potential: A Buy Rating Amid Product Discontinuation and Promising Innovations

Jayson BedfordRaymond James

Raymond James

$121

Buy

19.36%

Upside

Reiterated

05/27/25

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Haemonetics (HAE)

Rick WiseStifel Nicolaus

Stifel Nicolaus

$115→$120

Buy

18.38%

Upside

Reiterated

05/27/25

Stifel Nicolaus Keeps Their Buy Rating on Boston Scientific (BSX)

Patrick WoodMorgan Stanley

Morgan Stanley

$120→$125

Buy

23.31%

Upside

Reiterated

05/16/25

Morgan Stanley Sticks to Its Buy Rating for Boston Scientific (BSX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

1 Month

xxx

Success Rate

20/28 ratings generated profit

Average Return

+3.25%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +3.25% per trade.

3 Months

xxx

Success Rate

22/27 ratings generated profit

Average Return

+8.22%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.48% of your transactions generating a profit, with an average return of +8.22% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

22/23 ratings generated profit

Average Return

+32.16%

reiterated a buy rating 2 months ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +32.16% per trade.

2 Years

xxx

Success Rate

29/30 ratings generated profit

Average Return

+52.80%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.67% of your transactions generating a profit, with an average return of +52.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BSX has received 37 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 120.29.

Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.72 with a range of $0.71 to $0.75. The previous quarter’s EPS was $0.75. BSX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BSX has Outperformed its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $4.89B with a range of $4.83B to $4.99B. The previous quarter’s sales results were $4.66B. BSX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year BSX has Outperformed its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 120.29.

What is BSX’s upside potential, based on the analysts’ average price target?

Boston Scientific has 18.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BSX a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Strong Buy which is based on 22 buy ratings, 1 hold ratings and 0 sell ratings.

What is Boston Scientific’s price target?

The average price target for Boston Scientific is 120.29. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $110.00. The average price target represents 18.66% Increase from the current price of $101.37.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of BSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Boston Scientific (BSX) Stock Forecast & Price Target

BSX Analyst Ratings

BSX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

BSX Analyst Recommendation Trends

BSX Financial Forecast

BSX Earnings Forecast

BSX Sales Forecast

BSX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts